Quotient Clinical Celebrates its 50th RapidFACT™ Program

kdm communications's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

Quotient Clinical, the Translational Pharmaceutics™ Company, has commenced its 50th RapidFACT (Rapid Formulation development And Clinical Testing) program – a significant milestone in the development of this service.


 February 10, 2014 - (PressReleasePoint) - Quotient Clinical, the Translational Pharmaceutics™ Company, has commenced its 50th RapidFACT (Rapid Formulation development And Clinical Testing) program – a significant milestone in the development of this service.
 
RapidFACT was first developed in 2008, with the goal of transforming the processes by which drug product formulations are optimized.  This service has now been proven to accelerate program timelines by at least fifty percent, and deliver significant associated cost savings.  This has been achieved by the co-location of real-time GMP manufacturing and clinical testing, under Quotient’s Translational Pharmaceutics™ platform, which enables formulation selection to be underpinned by emerging clinical data.
 
RapidFACT has been successfully deployed in early development and life cycle management programs to develop oral, inhaled, dermal and ocular drug products.  These programs have principally focussed on optimizing drug products for once- or twice-daily dosing, or on addressing problems related to poor solubility.  RapidFACT studies have been commissioned by customers ranging from large pharmaceutical organizations to small biotechs in the USA, Europe and Japan.
 
Mark Egerton, CEO of Quotient Clinical, commented: "RapidFACT was launched in response to the challenges our customers told us they were confronting in their development programs.  We are pleased that the potential benefits we identified in 2008 have translated into real timeline reductions and cost savings in all of our RapidFACT programs.  Ultimately, this approach is helping our customers to address many of the R&D productivity issues prevalent in the industry today."
 
For further information about Quotient Clinical, visit www.quotientclinical.com
Sarah Khan
kdm communications Ltd
Tel: + 44 (0)1480 405333
Sarahk@kdm-communications.com
 
Donna Geoghegan
Quotient Clinical
Tel: + 44 (0)115 9315102
Donna.Geoghegan@quotientclinical.com
 
About Quotient Clinical
 
Quotient Clinical offers a unique range of services, based on its Translational Pharmaceutics™ platform.  Translational Pharmaceutics™ integrates formulation development, real-time GMP manufacturing with clinical testing, significantly reducing the time and cost of bringing a drug to market.
 
For more than 20 years, Quotient Clinical has brought innovation to early drug development programs for pharmaceutical companies worldwide.  At the company’s purpose built facilities, real-time manufacturing of all types of dosage forms is co-located with its clinical pharmacology unit to maximise flexibility, speed and cost savings for clients. More than 200 highly trained specialists provide a full range of services from study set-up right through to data analysis and reporting.
 
For further information, visit www.quotientclinical.com


Press Contact:
Sarah Khan
kdm communications Ltd
Tel: + 44 (0)1480 40
http://www.kdm-communications.com/
*****@**m**o**u**c**i**s.com
Email partially hidden to block spam. Please use the contact form here.
Contact Sarah Khan
Email the contact person for this press release. Do not send spam or irrelevant message.
5 + 0 =


Copy this html code to your website/blog to embed this press release.

Comments

Post new comment

17 + 3 =